Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Michael L. Kendrick

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-7960-3254; OpenAlex author ID A5111504882. Sources: OpenAlex.

Their work

Papers
37 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
124
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 3 papers · 2022: 4 papers · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 3 papers

Papers 37

  1. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  2. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  3. Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma: Should Vein Abutment Matter? Co-author DOI 10.6004/jnccn.2025.7097↗
  4. Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/jso.27871↗
  5. Outcomes of Visceral Arterial Interposition Graft Reconstruction for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006350↗
  6. Long-Term Reoperation Rates Following Pancreatoduodenectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1177/00031348241304021↗
  7. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1245/s10434-025-17036-y↗
  8. Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine-based neoadjuvant chemotherapy in pancreatic cancer patients. Co-author DOI 10.1002/jso.27837↗
  9. Quality of Life and Gastrointestinal Symptoms in Long-term Survivors of Pancreatic Cancer Following Pancreatoduodenectomy. Co-author DOI 10.1097/sla.0000000000006053↗
  10. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-023-14875-5↗
  11. Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients. Co-author DOI 10.1097/xcs.0000000000000704↗
  12. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot St… Co-author DOI 10.1245/s10434-022-12328-z↗
  13. Oncologic Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Highly Selected Patients with Metastatic Pancreatic Ductal Adenoc… Co-author DOI 10.1245/s10434-023-14138-3↗
  14. Pancreatic Cancer is More Frequently Early Stage at Diagnosis in Surgically Resected Intraductal Papillary Mucinous Neoplasms With Preoperative Surveillance. Co-author DOI 10.1016/j.gastha.2022.07.004↗
  15. Patency rates of hepatic arterial resection and revascularization in locally advanced pancreatic cancer. Co-author DOI 10.1016/j.hpb.2022.06.005↗
  16. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10991-2↗
  17. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  18. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer. Co-author DOI 10.1002/cam4.4144↗
  19. Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinica… Co-author DOI 10.1016/j.jamcollsurg.2021.05.009↗
  20. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. First author DOI 10.1097/sla.0000000000003284↗
  21. En Bloc Celiac Axis Resection for Pancreatic Cancer: Classification of Anatomical Variants Based on Tumor Extent. Last author DOI 10.1016/j.jamcollsurg.2020.05.005↗
  22. Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.11.003↗
  23. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Co-author DOI 10.1016/j.surg.2019.12.008↗
  24. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Last author DOI 10.1002/jso.25681↗
  25. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Canc… Co-author DOI 10.1038/s41395-018-0403-2↗
  26. Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-018-3695-z↗
  27. Endoscopic Ultrasound Fine-Needle Aspiration Diagnosis of Synchronous Primary Pancreatic Adenocarcinoma and Effects on Staging and Resectability. Co-author DOI 10.1016/j.cgh.2016.08.009↗
  28. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1016/j.gie.2016.11.014↗
  29. Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5762-6↗
  30. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.11.003↗
  31. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and a… Co-author DOI 10.1016/j.jamcollsurg.2016.02.009↗
  32. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chem… Co-author DOI 10.1016/j.surg.2016.06.010↗
  33. Laparoscopic Pancreaticoduodenectomy: Is It an Effective Procedure for Pancreatic Ductal Adenocarcinoma? First author DOI 10.1016/j.yasu.2015.03.003↗
  34. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Last author DOI 10.1097/sla.0000000000000937↗
  35. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. First author DOI 10.1007/s11605-012-1853-2↗
  36. Laparoscopic and robotic resection for pancreatic cancer. Co-author DOI 10.1097/ppo.0b013e31827b8f86↗
  37. Patterns of pancreatic resection differ between patients with familial and sporadic pancreatic cancer. Co-author DOI 10.1007/s11605-011-1417-x↗

Closest collaborators

The 25 strongest of 124 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark Joseph Truty · 29 shared papers, 2014–2026 · strength 4.19
  2. Cornelius A. Thiels · 14 shared papers, 2021–2026 · strength 2.68
  3. Sean Patrick Cleary · 16 shared papers, 2020–2025 · strength 2.42
  4. Susanne Gray Warner · 11 shared papers, 2022–2026 · strength 2.19
  5. Travis Edward Grotz · 10 shared papers, 2020–2025 · strength 1.50
  6. Jennifer A. Yonkus · 9 shared papers, 2021–2025 · strength 1.48
  7. Roberto Alva‐Ruiz · 7 shared papers, 2021–2025 · strength 1.10
  8. Amro M. Abdelrahman · 6 shared papers, 2021–2025 · strength 0.88
  9. Robert R. McWilliams · 6 shared papers, 2020–2025 · strength 0.82
  10. Jennifer L. Leiting · 5 shared papers, 2021–2026 · strength 0.80
  11. Chi Zhang · 3 shared papers, 2024–2025 · strength 0.69
  12. Michael B. Farnell · 11 shared papers, 2011–2019 · strength 0.66
  13. Andrea Zironda · 3 shared papers, 2024–2025 · strength 0.64
  14. Suresh T. Chari · 7 shared papers, 2017–2022 · strength 0.58
  15. Bernardo C. Mendes · 3 shared papers, 2020–2025 · strength 0.49
  16. Rondell Patrell Graham · 4 shared papers, 2021–2022 · strength 0.48
  17. Christopher Leigh Hallemeier · 4 shared papers, 2016–2022 · strength 0.42
  18. Amit Mahipal · 3 shared papers, 2021–2023 · strength 0.42
  19. Ferga C. Gleeson · 5 shared papers, 2017–2022 · strength 0.41
  20. Michael J. Levy · 5 shared papers, 2017–2022 · strength 0.41
  21. Naoki Takahashi · 5 shared papers, 2017–2020 · strength 0.40
  22. Santhi Swaroop Vege · 4 shared papers, 2017–2022 · strength 0.38
  23. Freek D. Daams · 2 shared papers, 2026 · strength 0.37
  24. Ingmar Florin Rompen · 2 shared papers, 2026 · strength 0.37
  25. Oskar Franklin · 2 shared papers, 2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.